2022
Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis
Kanbay M, Yildiz AB, Siriopol D, Vehbi S, Hasbal NB, Kesgin YE, Celayir M, Selcukbiricik F, Covic A, Perazella MA. Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. International Urology And Nephrology 2022, 55: 1025-1032. PMID: 36282399, DOI: 10.1007/s11255-022-03395-y.Peer-Reviewed Original ResearchConceptsAcute kidney injuryImmune checkpoint inhibitorsSolid organ malignanciesCheckpoint inhibitorsKidney injuryOrgan malignanciesNephrotoxic agentsSingle-center retrospective cohort studyType of ICIBaseline serum creatinine levelAcute interstitial nephritisLocation of malignancyRetrospective cohort studySerum creatinine levelsKidney function recoveryRenal replacement therapyUrinary tract obstructionRisk of mortalityICPI treatmentRenal prognosisTract obstructionCohort studyCreatinine levelsFive patientsInterstitial nephritisDiagnosis and management of immune checkpoint inhibitor-associated acute kidney injury
Sprangers B, Leaf DE, Porta C, Soler MJ, Perazella MA. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nature Reviews Nephrology 2022, 18: 794-805. PMID: 36168055, DOI: 10.1038/s41581-022-00630-8.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAcute kidney injuryKidney injuryKidney biopsyAcute tubulo-interstitial nephritisImmune-related adverse eventsConcomitant anticancer therapyTubulo-interstitial nephritisEffector T cellsEvaluation of patientsLoss of toleranceCheckpoint inhibitorsPartial remissionPermanent discontinuationAdverse eventsMost patientsAppropriate treatmentEarly initiationT cellsClinical practiceFavorable responsePatientsAccurate diagnosisCancer treatmentAnticancer therapyThe association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Kanbay M, Copur S, Siriopol D, Yildiz A, Berkkan M, Popa R, Hasbal N, Ortiz A, Perazella M. The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Clinical Kidney Journal 2022, 16: 817-826. PMID: 37151409, PMCID: PMC10157786, DOI: 10.1093/ckj/sfac194.Peer-Reviewed Original ResearchAcute kidney injuryImmune checkpoint inhibitorsEffect of AKICheckpoint inhibitorsCancer patientsKidney injuryDevelopment of AKISystematic reviewImmune checkpoint inhibitor therapySevere acute kidney injuryPersistent kidney dysfunctionSevere AKI patientsCheckpoint inhibitor therapyRisk of deathNon-randomized studiesCochrane Library databasesRisk of mortalityNovel therapeutic approachesWeb of ScienceAKI patientsICPI treatmentCause mortalityInhibitor therapyKidney dysfunctionMortality outcomes
2021
Immunotherapy-Related Acute Kidney Injury
Manohar S, Jhaveri KD, Perazella MA. Immunotherapy-Related Acute Kidney Injury. Advances In Kidney Disease And Health 2021, 28: 429-437.e1. PMID: 35190109, DOI: 10.1053/j.ackd.2021.07.006.Peer-Reviewed Original ResearchConceptsChimeric antigen receptor T-cell therapyEffective immune checkpoint inhibitorsAcute kidney injuryImmune checkpoint inhibitorsHigh-dose interleukinNumerous clinical trialsT-cell therapyField of oncologyCheckpoint inhibitorsKidney injuryGeneration immunotherapiesClinical trialsClinical practiceImmunotherapyImmune systemAdverse effectsNephrotoxicityInterleukinPathophysiologyInjuryTherapyCancerOncologyTrialsCheckpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations
Perazella MA, Sprangers B. Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations. Clinical Kidney Journal 2021, 14: 1301-1306. PMID: 33970161, PMCID: PMC8087122, DOI: 10.1093/ckj/sfab052.Peer-Reviewed Original ResearchAcute kidney injuryImmune checkpoint inhibitorsAcute tubulointerstitial nephritisKidney biopsyImmune-related adverse eventsVall d'Hebron University HospitalSingle-center studyNoninvasive diagnostic markerEvidence-based recommendationsAKI patientsICI rechallengeNephrology servicesCheckpoint inhibitorsICI treatmentKidney injuryAdverse eventsTubulointerstitial nephritisNonhematologic malignanciesUniversity HospitalTreatment protocolClinical practicePatientsOptimal managementDiagnostic markerCancer treatment
2020
Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
Herrmann SM, Perazella MA. Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. Kidney International Reports 2020, 5: 1139-1148. PMID: 32775813, PMCID: PMC7403510, DOI: 10.1016/j.ekir.2020.04.018.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsAcute kidney injuryCheckpoint inhibitorsAdverse renal effectsAdverse renal eventsSubset of patientsPotential risk factorsAcute rejectionRenal eventsKidney injuryRenal effectsTransplant populationRenal toxicityRisk factorsBetter outcomesPatientsNephrotoxicityCliniciansCancer therapyCancerRecent studiesInhibitorsCurrent informationComplicationsProviders18 Adverse kidney effects of immunotherapies
SALY D, PERAZELLA M. 18 Adverse kidney effects of immunotherapies. 2020, 166-182.e3. DOI: 10.1016/b978-0-323-54945-5.00027-8.Peer-Reviewed Original ResearchKidney diseaseDrug-induced kidney diseaseHigh-dose interleukin-2B-cell acute lymphoblastic leukemiaChimeric antigen receptor T cellsAntigen receptor T cellsAdverse kidney effectsImmune checkpoint inhibitorsChronic kidney diseaseChronic kidney injuryNumber of medicationsReceptor T cellsAcute lymphoblastic leukemiaConventional chemotherapeutic drugsAcid-base disturbancesOlder immunotherapiesCheckpoint inhibitorsKidney injuryNovel immunotherapiesNew immunotherapiesCancer patientsKidney effectsKidney lesionsLymphoblastic leukemiaImmune cells
2018
The adverse kidney effects of cancer immunotherapies
Saly D, Perazella M. The adverse kidney effects of cancer immunotherapies. Journal Of Onco-Nephrology 2018, 2: 56-68. DOI: 10.1177/2399369318808806.Peer-Reviewed Original ResearchChronic kidney diseaseKidney diseaseCancer immunotherapyInterleukin-2High-dose interleukin-2Chimeric antigen receptor T cellsAntigen receptor T cellsMore effective treatment optionsAdverse kidney effectsImmune checkpoint inhibitorsAcute kidney diseaseEffective treatment optionReceptor T cellsCase-based reviewCancer therapyGroup of drugsNew cancer immunotherapiesCancer treatment armamentariumConventional chemotherapeutic drugsList of cancersOlder immunotherapiesCheckpoint inhibitorsTreatment armamentariumNew immunotherapiesTreatment options